Acute myeloid leukemia

September 30, 2021
Patient and doctor talking

Trial Spotlight: Selina Luger on the PrE0905 Study for FLT3 Mutated Acute Myeloid Leukemia

This phase II trial is exploring the targeted cancer therapy gilteritinib, a tyrosine kinase inhibitor that kills leukemia cells by binding to the mutant FLT3 protein and blocking its activity
June 10, 2020
PrECOG logo

Now Enrolling: PrE0905 for Acute Myeloid Leukemia

This phase II study is exploring the potent FLT3 inhibitor gilteritinib